top of page
For most cost-effective consulting services:
Click here
Home
All News
Pharma
US FDA Approvals
North America
China Drug Approvals
Japan Drug Approvals | Healthcare
India Drug Approvals
APAC - Drug Approvals
LACAM
Europe
Canada Drug Healthcare News
Brazil - Drug approvals
EMA News
APAC
Therapy News
Immunology
Neurology
Oncology
Kidney Diseases
Cardiovascular
Infections_Vaccines
Metabolic Diseases
Women Health
Healthcare News
US Healthcare News
US Payer News
Europe Healthcare News
NICE Assessment Outcomes
G-BA Assessment Outcomes
APAC - Healthcare News
Lacam Healthcare News
Healthcare Policies
Conferences
About
All Posts
Healthcare Systems
News
Conferences
Know your disease
COVID
Japan drug approvals
USA Pharma News | Healthcare News
Europe Pharma News
Japan drug approvals
Australia Pharma & Healthcare News
Canada Pharma and Healthcare News
Asia | Pharma | Healthcare News
Indication News
Latam
US FDA News
CMS News
India Drug Healthcare
China Drug Approvals
Europe Healthcare News
APAC Drug approvals
US_PayerNews
Australia TGA Approvals
Biosimilars
Radioligand therapy
Chikungunya News
NICE recommendations
G-BA Assessment Outcomes
HAS Assessment Outcomes
Neurology
Immunology
Search
Orpathys wins conditional NMPA approval for MET‑amplified gastric cancer in China | iPharmaCenter
Badari Andukuri
Jul 8
Optum Financial Adds Alegeus Platform To Deepen Consumer Health Benefits And Payments | iPharmaCenter
Badari Andukuri
Jul 6
Myricx Bio Deal Brings Novel N‑Myristoyltransferase Inhibitor ADCs Into Novartis Portfolio | iPharmaCenter
Badari Andukuri
Jul 6
Enhertu Gains EU Tumour‑Agnostic Approval For HER2‑Positive Metastatic Solid Tumours | iPharmaCenter
Badari Andukuri
Jun 29
NICE Opens Access to New Immunotherapy in Cervical Cancer and First Disease‑Modifying Drug in Early Type 1 Diabetes
Badari Andukuri
Jun 28
Hospital and Drug Costs Outpace Contributions in Germany, Raising Pressure on Pharma Pricing
Badari Andukuri
Jun 27
CVS Pharmacy Joins Medicare GLP-1 Bridge and Scales Weight‑Loss Access Across the U.S. | iPharmaCenter
Badari Andukuri
Jun 27
June 2026: CHMP Signals New Options in CLL, TNBC and Multiple Myeloma
Badari Andukuri
Jun 27
Medicare GLP‑1 Bridge Program: Eligibility, Costs, and Drug Details | iPharmaCenter
Badari Andukuri
Jun 25
Merck Advances Pipeline with Tulisokibart Phase 3 Data and EU Nod for Keytruda-Padcev | iPharmaCenter
Badari Andukuri
Jun 24
CDSCO Approves AstraZeneca's Enhertu as New First-Line Combination for HER2-Positive Breast Cancer in India
Badari Andukuri
Jun 24
Japan Approves Sanofi’s Wayrilz for Chronic Immune Thrombocytopenia Treatment | iPharmaCenter
Badari Andukuri
Jun 23
AbbVie to Acquire Apogee Therapeutics in $10.9 Billion Immunology Deal | iPharmaCenter
Badari Andukuri
Jun 22
China Clears Vanflyta for FLT3-ITD Positive AML, Marking a New Option in Targeted Leukemia Care | iPharmaCenter
Badari Andukuri
Jun 19
FDA Clears Sanofi’s Tzield as First Disease-Modifying Therapy for Stage 3 Type 1 Diabetes | iPharmaCenter
Badari Andukuri
Jun 17
Takeda's Zasocitinib achieved over 2.5 times the PASI 100 rate of deucravacitinib in a head‑to‑head Ph3 psoriasis trial | iPharmaCenter
Badari Andukuri
Jun 12
EU Launches Era of Centralized HTA with First Joint Clinical Assessment of Ojemda | iPharmaCenter
Badari Andukuri
Jun 11
EULAR Annual Meeting in London, UK | 2026 | News | Updates | iPharmaCenter
Badari Andukuri
Jun 9
Best-Selling Cancer Drugs 2025: Top 10 by Revenue
Badari Andukuri
Jun 4
American Society of Clinical Oncology (ASCO) Annual Meeting | Chicago | 2026
Badari Andukuri
May 30
bottom of page
